vaccino antipoliomielitico ism
nuovo istituto sieroterapico milanese s.r.l. - vaccini poliomielitici - vaccini poliomielitici
vaccino bcg berna
istituto sieroterapico e vaccinogeno svizzero berna - vaccini della tubercolosi - vaccini della tubercolosi
vaccino colerico berna
istituto sieroterapico e vaccinogeno svizzero berna - vaccino colerico - vaccino colerico
vaccino anticolerico isi
istituto sierovaccinogeno italiano i.s.i. s.p.a. - vaccino colerico - vaccino colerico
vaccino behring colera
behringwerke ag - vaccini colerici - vaccini colerici
vaccino meningococcico polisaccaridico tetravalente gsk
glaxosmithkline biologicals s.a. - vaccino meningococcico - vaccino meningococcico
celvapan
nanotherapeutics bohumil, s.r.o. - whole virion influenza vaccine, inactivated containing antigen of strain a/california/07/2009 (h1n1)v - disease outbreaks; influenza, human; immunization - vaccini - profilassi dell'influenza causata dal virus a (h1n1) v 2009. celvapan dovrebbe essere usato in conformità con le linee guida ufficiali.
focetria
novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - vaccini contro l'influenza - profilassi dell'influenza causata dal virus a (h1n1v) 2009. focetria dovrebbe essere usato in conformità con le linee guida ufficiali.
gardasil 9 sospensione iniettabile in siringa preriempita
msd merck sharp & dohme ag - proteinum l1 papillomaviri dell'essere umano di tipo 6, proteinum l1 papillomaviri del tipo umano 11, proteinum l1 papillomaviri dell'essere umano di tipo 16, proteinum l1 papillomaviri tipo umano 18, proteinum l1 papillomaviri tipo umano 31, proteinum l1 papillomaviri tipo umano 33, proteinum l1 papillomaviri tipo umano 45, proteinum l1 papillomaviri umano di tipo 52, proteinum l1 papillomaviri tipo umano 58 - sospensione iniettabile in siringa preriempita - proteinum l1 papillomaviri humani typus 6 30 µg, proteinum l1 papillomaviri humani typus 11 40 µg, proteinum l1 papillomaviri humani typus 16 60 µg, proteinum l1 papillomaviri humani typus 18 40 µg, proteinum l1 papillomaviri humani typus 31 20 µg, proteinum l1 papillomaviri humani typus 33 20 µg, proteinum l1 papillomaviri humani typus 45 20 µg, proteinum l1 papillomaviri humani typus 52 20 µg, proteinum l1 papillomaviri humani typus 58 20 µg, aluminium ut aluminii hydroxyphosphas sulfas amorphus, natrii chloridum, histidinum, polysorbatum 80, natrii boras, aqua ad iniectabile ad suspensionem pro 0.5 ml corresp. natrium 3.78 mg. - papillomavirus umano vaccino (tipi 6, 11, 16, 18, 31, 33, 45, 52, 58) - vaccini
spikevax (previously covid-19 vaccine moderna)
moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccini - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.